PositiveID Commences Production of
Next Generation Caregiver Thermometer with Bluetooth Capability
Bluetooth-enabled Caregiver Device
Holds Potential to Disrupt the $1 Billion Thermometry Market
DELRAY BEACH, FL -- December 6, 2017 -- InvestorsHub NewsWire
-- PositiveID Corporation (OTC:
PSID), a life sciences company focused on detection and
diagnostics, is excited to announce that its Thermomedics
subsidiary has commenced production of its disruptive, next
generation Caregiver thermometer with Bluetooth capability.
Caregiver with Bluetooth will be commercially available in January
2018.
Management believes its newest manifestation of the Caregiver
product line is an important design advancement. The new device can
connect wirelessly to electronic health records systems and patient
monitoring stations in hospitals to transmit temperature readings
automatically into a patient's record. According to recent research
by MarketsandMarkets, the Bluetooth Smart and Smart Ready market is
expected to be worth $5.34 billion by 2023. Product teams able to
elevate next generation devices to take advantage of this trend
often experience a corresponding increase in market adoption.
"Incorporating wireless communication of temperature readings is
a logical next step for our Caregiver product," says Gary O'Hara,
Chief Technology Officer of Thermomedics. "By offering hospitals
and clinics the ability to connect and transmit data seamlessly to
patient monitoring stations, we eliminate extra steps for
healthcare professionals, enabling them to spend more time on
patient care, decreasing the likelihood of errors."
PositiveID's FDA-cleared Caregiver is a professional-grade,
infrared thermometer capable of delivering an oral-equivalent
temperature directly from the forehead in one to two seconds.
The lack of skin contact and absence of probe cover supplies
eliminate two chief concerns of healthcare facilities related to
thermometry: the risk of cross-contamination of highly-infectious
diseases such as Ebola, and unnecessary costs related to probe
covers as much as $0.10 per temperature, or an estimated $250 per
year per device.
PositiveID executives believe its next generation
Bluetooth-enabled model holds the potential to boost adoption of
the Caregiver line to take advantage of the growing use of infrared
thermometry, which is the fastest growing segment of the $1 billion
global temperature monitoring device market.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics
company with an extensive patent portfolio. PositiveID develops
biological detection and diagnostics systems, specializing in the
development of microfluidic systems for the automated preparation
of and performance of biological assays. PositiveID is also a
leader in the mobile technology vehicle market, with a focus on the
laboratory market and homeland security. For more information on
PositiveID, please visit http://www.psidcorp.com, or connect
with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID's future expectations, including the
likelihood that the Bluetooth-enabled Caregiver device holds the
potential to disrupt the $1 billion thermometry market; the
likelihood that the Bluetooth-enabled Caregiver will be
commercially available in January 2018; the likelihood that the
Bluetooth Smart and Smart Ready market is expected to be worth
$5.34 billion by 2023; the likelihood that product teams able to
elevate next generation devices to take advantage of this trend
often experience a corresponding increase in market adoption; the
likelihood that Caregiver can offer savings of $250 or more per
year per device in probe cover supplies alone; the likelihood that
the next generation Bluetooth-enabled model holds the potential to
boost adoption of the Caregiver line to take advantage of the
growing use of infrared thermometry, which is the fastest growing
segment of the $1 billion global temperature monitoring device
market; constitute "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934, and as that term is defined in the
Private Litigation Reform Act of 1995. Such forward-looking
statements involve risks and uncertainties and are subject to
change at any time, and PositiveID's actual results could differ
materially from expected results. These risks and uncertainties
include, without limitation, the Company's ability to attract new
customers and retain existing customers; the Company's ability to
target the professional healthcare market; the Company's ability to
raise capital; as well as other risks. Additional information about
these and other factors that could affect the Company's business is
set forth in the Company's various filings with the Securities and
Exchange Commission, including those set forth in the Company's
10-K filed on March 31, 2017, and 10-Qs filed on November 13, 2017,
August 14, 2017, and May 15, 2017, under the caption "Risk
Factors." The Company undertakes no obligation to update or release
any revisions to these forward-looking statements to reflect events
or circumstances after the date of this statement or to reflect the
occurrence of unanticipated events, except as required by law.
Contact:
PositiveID Corporation
Allison Tomek
(561) 805-8044
atomek@psidcorp.com